LRRK2 and Parkinson disease: This indicates that enhanced Rit2 expression counteracts pS129-aSyn accumulation not only in recombinant neuroblastoma cell lines, but importantly also in an in vivo PD mouse model, providing effective neuroprotection in a non-LRRK2 modeling paradigm.